Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00000174
Recruitment Status : Completed
First Posted : November 1, 1999
Last Update Posted : June 24, 2005
Information provided by:
National Institute on Aging (NIA)

Brief Summary:

This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease (AD) in subjects taking Exelon vs. placebo. Exelon is currently under review with the U.S. Food and Drug Administration as a treatment for Alzheimer's disease. The drug has been cleared for marketing in more than 40 countries for Alzheimer's disease to date, including all 15 member states of the European Union, New Zealand, Argentina, Brazil and Mexico.

Each subject with MCI will be randomly assigned to treatment with either Exelon or placebo. Subjects assigned to Exelon will receive 1.5 to 6.0 mg bid (twice daily) (3.0 to 12 mg/day) for the majority of the study. At every regular visit scheduled every three months, patients will be given basic efficacy and safety assessments. These assessments will include evaluation of adverse events, vital signs, activities of daily living, and clinical staging scales to determine if the subject may have converted to dementia.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Cognition Disorders Drug: Rivastigmine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Are aged 55-85 years, inclusive. Subjects older than 85 years may be eligible to participate, with approval of the designated study medical monitor.
  • Are male or female without child-bearing potential (i.e., surgically sterilized [via bilateral tubal ligation,bilateral oophorectomy, or hysterectomy], at least one year postmenopausal, or using adequate birth control).
  • Are cooperative, able to ingest oral medication, and willing to complete all aspects of the study.
  • Will provide written informed consent prior to their participation in the study.
  • Show evidence of mild cognitive impairment (MCI) by meeting all of the following criteria: Global CDR score = 0.5, NYU Delayed Paragraph Recall less than 9, 17-item HAM-D score less than 13, and HAM-D Item 1 (depressed mood) score =1.
  • Have a friend or family member who is willing to participate in the study as an informant. The informant must see the subject at least once a week for several hours and be available to accompany the subject to the screening and baseline visits, and at a minimum, be accessible by telephone for other scheduled visits.

Exclusion Criteria:

  • Advanced, severe, and unstable disease of any type that may interfere with primary and secondary variable evaluations including any medical condition that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical or mental status of the subject to a significant degree or put the subject at special risk.
  • Cognitive impairment sufficient to warrant a diagnosis of dementia.
  • Met the DSM-IV and NINCDS-ADRDA criteria for AD.
  • A clinical diagnosis of AD.
  • A DSM-IV Axis 1 diagnosis. However, subjects with current depression are eligible after appropriate treatment of the depressive episode. A minimum of four weeks washout of antidepressant medication should occur prior to screening. Subjects with a prior history of depression (but not currently depressed) are allowed in the study.
  • Fewer than four years of formal education.
  • A documented history of transient ischemic attacks.
  • Baseline MRI findings or CT-scan findings within a year of screening that are consistent with a process other than AD, e.g., stroke, tumor, brain trauma or hydrocephalus, that may contribute to the subject's MCI. Lacunae infarcts present in areas affecting cognition (entorhinal cortex, hippocampus, medial temporal lobe) will also exclude the subject from the study.
  • A score of greater than 4 on the Modified Hachinski Ischemic Scale.
  • A current diagnosis of any primary neurodegenerative disorder, e.g., Parkinson's disease.
  • A current diagnosis of uncontrolled seizure disorder.
  • A current diagnosis of active peptic ulceration.
  • A current diagnosis of severe and unstable cardiovascular disease.
  • A current diagnosis of sick-sinus syndrome or conduction deficits (sino-atrial block, second or third degree atrio-ventricular block).
  • A current diagnosis of acute, severe, or unstable asthmatic conditions.
  • A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to Exelon or to other cholinergic compounds (e.g., pilocarpine, bethanechol, tacrine, velnacrine, donepezil, metrifonate, or physostigmine). Subjects who have experienced elevations in liver function test parameters on other cholinesterase inhibitors are still eligible.
  • Taken any of the following substances: An investigational drug during the past four weeks; Metrifonate during the past three months; a drug or treatment known to cause major organ system toxicity during the past four weeks; other cholinergic drugs (e.g., donepezil, tacrine, succinylcholine-type muscle relaxants) during the past two weeks (topical pilocarpine will be permitted); antidepressant medication during the past four weeks.
  • Participated in a previous clinical trial of Exelon.
  • Clinically important laboratory abnormalities in serum B12, folate, or T3/T4 at screening. The subject should be excluded if peripheral neuropathy, macrocytic anemia, or myxedema is present.
  • If screen values do not meet the absolutely exclusionary values given below but are still outside the normal reference range, treatment for folic acid/B12 deficiency or thyroid disorder, as appropriate, may be initiated or adjusted with re-evaluation of the subject within three months. Within these three months of treatment, the subject's cognitive condition must be clinically unchanged or worse for the subject to be acceptable. Once accepted, the subject must remain on the appropriate treatment throughout the study.
  • Exclude if T3 uptake is less than 19%; T4 less than 2.9 ((g/dL); free T4 index is less than 0.8
  • Exclude if folate less than 1.7 ng/ml (normal range greater than 1.9)
  • Exclude if B12 less than 100 pg/ml (normal range greater than 200)
  • A positive rapid plasmin reagin test followed up by a positive serological test for syphilis.
  • A disability that may prevent the subject from completing all study requirements (e.g., blindness, deafness, severe language difficulty).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00000174

Layout table for location information
United States, Arizona
Medici Research Centers
Peoria, Arizona, United States, 85381
United States, California
University of California, Irvine
Orange, California, United States, 92868
United States, Colorado
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80220
United States, Florida
Neuromedical Research Institute (Offices in Ft. Lauderdale, Miami Beach and Boca Raton)
Ft. Lauderdale, Florida, United States, 33321
Miami Research Associates
Miami, Florida, United States, 33176
Center for Clinical Trials and Research
Venice, Florida, United States, 34285
United States, Indiana
Indiana University Alzheimer's Center
Indianapolis, Indiana, United States, 46202
United States, Missouri
St. Louis University
St. Louis, Missouri, United States, 63104
United States, New Jersey
Alzheimer's Research Corporation
Lakewood, New Jersey, United States, 08701
United States, New York
NYU Medical Center
New York, New York, United States, 10016
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Oklahoma
Pahl Brain Associates, P.C.
Oklahoma City, Oklahoma, United States, 73118
United States, Pennsylvania
Clinical Studies, Ltd., Philadelphia
Philadelphia, Pennsylvania, United States, 19106
United States, Texas
St. Paul Medical Center
Dallas, Texas, United States, 75235
United States, Washington
University of Washington, Seattle
Seattle, Washington, United States, 98108
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Steven Ferris, PhD NYU Langone Health
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00000174    
Other Study ID Numbers: IA0012
First Posted: November 1, 1999    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: January 2000
Keywords provided by National Institute on Aging (NIA):
Mild cognitive impairment
Alzheimer's disease
Cholinergic agents
Cholinesterase inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognition Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents